Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the promise of blood-based biomarkers for treatment monitoring. Data has been presented on plasma phosphorylated-tau 217 (p-tau217) as a method to monitor the effects of lecanemab and donanemab. This research is investigating if medication discontinuation is feasible if p-tau217 is reduced to a certain level. However, further research is needed to address several questions within this area. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
View Content